Brought to you by:
SEISMIQ IVL offers targeted approach to increasingly complex PAD
This video is sponsored by Boston Scientific. Nicolas Mouawad, MD, chief of vascular surgery at McLaren Health in Bay City, Michigan, discussed the growing challenge of treating peripheral artery disease (PAD) as an aging patient population presents with increasingly complex,…
Study reveals higher PAD detection rates in women despite similar risk profiles
Women may be more likely than men to have undiagnosed peripheral artery disease (PAD) at the time of screening, despite meeting similar risk criteria, according to new data from a community-based screening program targeting underserved populations. The study analyzed participants…
Pioneering Florida limb preservation program laser-focuses on evidence-based, customized care for PAD
This advertorial is sponsored by Tampa General Hospital. As the prevalence of peripheral arterial disease (PAD) continues to climb across the U.S. and globally, a pioneering limb preservation program in south Florida is sharpening its resolve to provide cutting-edge treatment…
Endologix announces 36-month results of DETOUR2 study
Endologix has announced the final 36-month results from the DETOUR2 study—a prospective, single-arm, international, multicentre clinical evaluation of the novel Detour system for fully percutaneous femoropopliteal bypass procedures. A press release details that the findings highlight the durable efficacy of…
Bolt Medical announces completion of RESTORE ATK and RESTORE BTK pivotal studies investigating Bolt IVL system
Bolt Medical has announced the completion and results of the RESTORE ATK and RESTORE BTK pivotal clinical trials investigating the company’s Bolt intravascular lithotripsy (IVL) above-the-knee (ATK) and below-the-knee (BTK) systems for the treatment of peripheral arterial disease (PAD) in…
Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for below-the-knee arteries
Presented today, late-breaking data from the second year of the LIFE-BTK clinical trial demonstrate the long-term effectiveness of the US Food and Drug Administration (FDA)-approved Esprit BTK everolimus-eluting resorbable scaffold system (Abbott Vascular) in patients with the most severe form…
FDA grants R3 Vascular IDE approval for ELITE-BTK pivotal trial of Magnitude drug-eluting bioresorbable scaffold
R3 Vascular today announced that the Food and Drug Administration (FDA) has granted investigational device exemption (IDE) approval to initiate its ELITE-BTK pivotal trial of the next-generation Magnitude drug-eluting bioresorbable scaffold for below-the-knee (BTK) peripheral arterial disease (PAD). “We are…
Novel RCT framework set to improve design and reporting of endovascular infrainguinal lower-limb interventions for PAD
Pilot testing has shown that a new framework—dubbed Endo-STAR—can be used to describe and standardise endovascular interventions for peripheral arterial disease (PAD) within a randomised controlled trial (RCT) protocol and monitor adherence to the protocol over the course of a…
New ESC guidelines combine peripheral arterial and aortic diseases for first time, emphasising interconnectivity of whole arterial system
The European Society of Cardiology (ESC) has today published its 2024 guidelines for the management of peripheral arterial and aortic diseases (PAAD), evaluating these vascular conditions together as part of the same cardiovascular system. The guidelines are aimed at cardiologists,…
Humacyte’s ATEV granted FDA Regenerative Medicine Advanced Therapy designation for advanced PAD
Humacyte recently announced it has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its investigational acellular tissue engineered vessel (ATEV), designed to treat patients with advanced peripheral arterial disease (PAD). This…